A Randomized, Multi-Center, Open-Label, Active-Controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) versus Octreotide LAR or Lanreotide ATG in Patients with Gastroenteropancreatic

Grants and Contracts Details

StatusFinished
Effective start/end date12/2/21 → 8/21/24

Funding

  • Fortrea Incorporated: $26,300.00